Evoke Pharma Inc Quarterly Debt-to-equity in % from Q2 2014 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Evoke Pharma Inc quarterly Debt-to-equity history and growth rate from Q2 2014 to Q3 2024.
  • Evoke Pharma Inc Debt-to-equity for the quarter ending September 30, 2024 was 475 %, a 15.1% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 475 -84.3 -15.1% Sep 30, 2024
Q2 2024 1.36K +1.1K +421% Jun 30, 2024
Q1 2024 6.14K +5.98K +3681% Mar 31, 2024
Q4 2023 -4.4K -4.56K -2855% Dec 31, 2023
Q3 2023 559 +399 +249% Sep 30, 2023
Q2 2023 261 +99 +61.2% Jun 30, 2023
Q1 2023 163 -38.3 -19.1% Mar 31, 2023
Q4 2022 160 -7.45 -4.45% Dec 31, 2022
Q3 2022 160 -117 -42.3% Sep 30, 2022
Q2 2022 162 -352 -68.6% Jun 30, 2022
Q1 2022 201 -1.6K -88.9% Mar 31, 2022
Q4 2021 167 Dec 31, 2021
Q3 2021 278 Sep 30, 2021
Q2 2021 514 Jun 30, 2021
Q1 2021 1.8K Mar 31, 2021
Q4 2018 29.8 -117 -79.7% Dec 31, 2018
Q3 2018 56.9 -77 -57.5% Sep 30, 2018
Q2 2018 121 +13.8 +12.9% Jun 30, 2018
Q1 2018 143 -22.3 -13.5% Mar 31, 2018
Q4 2017 147 -163 -52.6% Dec 31, 2017
Q3 2017 134 -197 -59.5% Sep 30, 2017
Q2 2017 107 -202 -65.2% Jun 30, 2017
Q1 2017 166 -13.9 -7.72% Mar 31, 2017
Q4 2016 309 +182 +142% Dec 31, 2016
Q3 2016 331 +232 +235% Sep 30, 2016
Q2 2016 309 +245 +383% Jun 30, 2016
Q1 2016 180 +142 +383% Mar 31, 2016
Q4 2015 128 +103 +408% Dec 31, 2015
Q3 2015 98.7 +81.4 +472% Sep 30, 2015
Q2 2015 64 +44.7 +231% Jun 30, 2015
Q1 2015 37.2 Mar 31, 2015
Q4 2014 25.2 Dec 31, 2014
Q3 2014 17.3 Sep 30, 2014
Q2 2014 19.3 Jun 30, 2014
* An asterisk sign (*) next to the value indicates that the value is likely invalid.